Xenical Will Be Used By Less Than 5% Of U.K. Obese Population, Roche Says
Executive Summary
Patient selection criteria in EU labeling for Roche's Xenical will allow a maximum of 5% of obese patients in the U.K. to be treated with orlistat, Roche Products Ltd Managing Director Vic Ackermann said at the Sept. 21 U.K. Xenical launch in London.